- Molecular NameAztreonam
- SynonymAZT
- Weight435.438
- Drugbank_IDDB00355
- ACS_NO78110-38-0
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-2.63
- pka-0.5, 2.7, 3.7
- LogD (pH=7, predicted)-7.62
- Solubility (experiment)9.98 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)0.36
- LogSw (predicted, AB/LogsW2.0)15.16
- Sw (mg/ml) (predicted, ACD/Labs)4.95
- No.of HBond Donors5
- No.of HBond Acceptors13
- No.of Rotatable Bonds7
- TPSA238.2
- StatusFDA approved
- AdministrationIntravenous and intramuscular
- PharmacologyA synthetic monocyclic beta-lactam antibiotic (a monobactam), with the nucleus based on a simpler monobactam isolated from Chromobacterium violaceum.
- Absorption_value1.0
- Absorption (description)Aztreonam is completely absorbed after intramuscular administration with peak concentrations reached within 1 h.
- Caco_2N/A
- Bioavailability1.0
- Protein binding56.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmOnly about 6 to 16% is metabolised to inactive metabolites by hydrolysis.
- Half life1.7 h
- Excretionhe drug is excreted predominantly in urine by renal tubular secretion and glomerular filtration; about 60 to 75% of a dose appears within 8 h as the unchanged drug with only small quantities of metabolites. Only small amounts of the unchanged drug and metabolites are excreted in faeces. It is removed by haemodialysis and to a lesser extent by peritoneal dialysis.
- Urinary ExcretionN/A
- Clerance93 ml/min; reduced in neonates.
- ToxicityThe following adverse reactions have been reported: rash, seizures, diarrhea, nausea, vomiting, pseudomembranous colitis, dyspnea.
- LD50 (rat)N/A
- LD50 (mouse)N/A